Endocrine Abstracts

Introduction: Impact of suppressive therapy with LH RH analogues is more stop the premature pubertal development, reduce the acceleration of bone maturation that compromises the final size and avoid psychological disturbances caused by hormonal imbalance.

Aim: To study the effects of treatment on pubertal development, bone maturation and evolution of the size during and at the end of treatment and final height in 20 patients with central precocious puberty treated by triptorelin.

Subjects and methods: 15 children (chronological age at diagnosis: 8±1.8 years) at the end of treatment (11±0.1 years) and the final size (15.9±2.5 years) were treated for a central precocious puberty. The selection criteria for this study were treatment of central precocious puberty by Decapeptyl during 2 years or more. We assessed pubertal status, size and bone maturation at the beginning and the final size after stop taking treatment.

Results: At the beginning of treatment, pubertal development was S3 (S2–S4, size +2.1±0.8 DS/TC) and AO/10.5±0.8 years. Under treatment, breast development decreased and bone maturation decelerated. The mean final height was 158.2±6.6 cm; – 1.5±0.1 DS/TC.

Discussion and conclusion: Treatment of central precocious puberty by GnRH agonists stabilizes or regressed pubertal development and decreases bone maturation rate. However when indicated late, the prognosis size is not satisfactory.